IL-10 Implications in Psoriasis
Abstract
Abstract: Interleukin (IL)-10 is a pluripotent cytokine with effects on numerous cell populations, in particular circulating and
resident immune cells as well as epithelial cells. With its potent immunoregulatory capacities, its main biological function seems
to be the limitation and termination of inammatory responses. Hence, its low level expression found in psoriasis may have
pathophysiological relevance to this immune disease. Remarkably, the induction of IL-10 expression was found by conventional
antipsoriatic therapies, supporting the hypothesis that it may be a key cytokine in psoriasis. Furthermore, the rst use in clinical
trials in patients with established psoriasis showed that it had moderate antipsoriatic effects and was well tolerated. Moreover,
long-term application in psoriatic patients in remission showed that it decreases the incidence of relapse and prolongs the
disease free interval. The IL-10 antipsoriatic activity is suggested to be due to the effects on different cell populations, including
antigen presenting cells and T-cells (type 1 / type 2 balance shift), but not through direct effects on keratinocytes. In conclusion,
IL-10 seems to have major clinical and therapeutic implications in psoriasis. Further multicenter, placebo-controlled, double blind
trials are required to be an established antipsoriatic therapy. We can come to the conclusion that IL-10 genetic polymorphism
and expression is potentially a key immune marker in psoriasis.
resident immune cells as well as epithelial cells. With its potent immunoregulatory capacities, its main biological function seems
to be the limitation and termination of inammatory responses. Hence, its low level expression found in psoriasis may have
pathophysiological relevance to this immune disease. Remarkably, the induction of IL-10 expression was found by conventional
antipsoriatic therapies, supporting the hypothesis that it may be a key cytokine in psoriasis. Furthermore, the rst use in clinical
trials in patients with established psoriasis showed that it had moderate antipsoriatic effects and was well tolerated. Moreover,
long-term application in psoriatic patients in remission showed that it decreases the incidence of relapse and prolongs the
disease free interval. The IL-10 antipsoriatic activity is suggested to be due to the effects on different cell populations, including
antigen presenting cells and T-cells (type 1 / type 2 balance shift), but not through direct effects on keratinocytes. In conclusion,
IL-10 seems to have major clinical and therapeutic implications in psoriasis. Further multicenter, placebo-controlled, double blind
trials are required to be an established antipsoriatic therapy. We can come to the conclusion that IL-10 genetic polymorphism
and expression is potentially a key immune marker in psoriasis.
Al-Robaee, A. A., Al-Zolibani, A. A., Al-Shobili, H. A., Kazamel, A., & Settin, A. (2008). IL-10 Implications in Psoriasis. International Journal of Health Sciences, 2(1). Retrieved from https://pub.qu.edu.sa/index.php/journal/article/view/70
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Copyright and license info is not available